Skip to content

Investor Relations / Publications


The following publications, posters and citations are provided for investors and should not be construed as marketing the use of any Amarin products or product candidates. Copyright to certain documents referenced below are held by their publishers. Where possible, a link is provided for access to further information about the respective publication. Note that AMR101 is the clinical name for VASCEPA® (icosapent ethyl) capsules. For more information about VASCEPA® (icosapent ethyl) capsules visit

For categorization of papers that support correlation between TG levels and CV risk, click here.


This page was last updated on September 9, 2020.

Amarin Corporation